Hormone Replacement Therapy is a treatment approach in which hormones are administered to replace or supplement hormones that the body is producing at insufficient levels or to achieve a defined therapeutic hormonal state. The phrase is used in several medical contexts, most commonly menopause-related treatment and replacement of deficient hormones, while hormone therapy can also be used in other specialised settings.
In menopause care, hormone therapy generally refers to administration of oestrogen, with a progestogen usually added for people who have a uterus when systemic oestrogen is used, because unopposed oestrogen can stimulate the endometrium and increase the risk of endometrial hyperplasia and cancer. Hormone replacement differs from using hormones for purposes unrelated to correcting deficiency, although the terminology can overlap. The appropriate preparation, route, dose and duration depend on the indication, anatomy, symptoms, risks, contraindications and treatment objectives.
Menopause-related hormone therapy can relieve vasomotor symptoms such as hot flushes and night sweats and can improve genitourinary symptoms associated with declining oestrogen. Systemic treatment circulates throughout the body and can affect multiple tissues, whereas local vaginal oestrogen is used primarily to treat genitourinary symptoms and generally results in much lower systemic exposure than systemic therapy.
Oestrogen can be administered orally or through transdermal preparations such as patches, gels or sprays, while local preparations can include creams, tablets or rings depending on the product. Progestogens may be administered in continuous or sequential regimens and can be combined with oestrogen in various formulations. Different regimens have different bleeding patterns, pharmacokinetic characteristics and risk profiles, so treatment selection is not simply a choice between equivalent products.
The historical development of hormone replacement reflects changing understanding of endocrine physiology, reproductive ageing and long-term hormone effects. Earlier hormone therapies were sometimes prescribed with broader claims than current evidence supports, while later large studies and subsequent analyses substantially refined understanding of benefits, risks, timing and patient selection. Modern practice generally focuses on symptom control and other clearly established indications rather than assuming that systemic hormone therapy should routinely be used to prevent every chronic disease associated with ageing. Evidence has also shown that outcomes can vary according to age, time since menopause, formulation, route, dose, duration and whether a progestogen is used. The modern concept is therefore more individualised than the historically simplified idea of replacing all declining hormones indefinitely.
Hormone replacement can involve several classes of hormones depending on the underlying deficiency or therapeutic objective. Oestrogen replacement can be required when endogenous oestrogen production is substantially reduced, while thyroid hormone replacement uses synthetic thyroid hormone to replace inadequate thyroid hormone activity and is a separate clinical application despite the shared phrase hormone replacement. Adrenal hormone replacement is used for adrenal insufficiency, and other endocrine deficiencies can similarly require replacement.
These therapies should not be treated as interchangeable because each hormone system has distinct physiology, dosing requirements and monitoring considerations. Hormone replacement also differs from hormone suppression, in which a hormone's production or action is deliberately reduced, and from hormone-modulating treatment, in which receptor activity is altered without simply replacing a missing hormone.
Risks associated with hormone replacement depend strongly on the treatment and clinical context. In menopause-related systemic therapy, risks can include venous thromboembolism, stroke and breast or endometrial effects, with the balance varying according to formulation, route, duration and patient characteristics. Oestrogen alone is generally used only when there is no uterus, whereas systemic oestrogen plus a progestogen is generally required when the uterus is present.
Transdermal oestrogen may have a different thrombotic risk profile from oral oestrogen because it bypasses first-pass hepatic metabolism, although treatment decisions require assessment of the individual's circumstances. Hormone therapy can also cause side effects such as breast tenderness, bloating, headaches or bleeding changes. The existence of possible risks does not mean treatment is inherently inappropriate; rather, therapy requires assessment of indication, benefits, contraindications and individual risk factors.
Hormone replacement is distinct from contraception, although some hormonal medicines can have both contraceptive and non-contraceptive effects. Menopause-related hormone therapy does not reliably provide contraception because its purpose and hormonal doses differ from contraceptive regimens. People who can become pregnant may remain potentially fertile during the menopausal transition even while experiencing symptoms associated with declining ovarian function. Some hormonal contraceptives can suppress ovulation and alter bleeding patterns, making clinical assessment of menopause more complicated. Treatment decisions therefore depend on whether the objective is symptom management, pregnancy prevention, replacement of endocrine deficiency, or another therapeutic purpose. Conflating these objectives can result in inappropriate assumptions about protection, dosing or expected physiological effects.
Assessment before hormone replacement generally includes identifying the indication, reviewing symptoms or evidence of deficiency, considering relevant medical history, examining risk factors and discussing alternatives and expected outcomes. For menopause-related symptoms in otherwise appropriate patients, treatment is often based substantially on clinical history rather than routine measurement of circulating hormone concentrations, because hormone levels fluctuate and may not correlate closely with symptom severity or treatment need.
Follow-up can assess symptom response, adverse effects, bleeding patterns where relevant and whether the treatment remains appropriate. Some conditions require specific laboratory monitoring, such as thyroid hormone replacement, where biochemical measurements help guide dose adjustment. Monitoring requirements therefore depend on the hormone, formulation, indication and clinical circumstances rather than following one universal hormone-testing protocol.
Hormone Replacement Therapy is best understood as a family of treatments rather than a single medicine. Its therapeutic logic is to restore or supplement hormonal signalling when that is clinically appropriate, but the biological consequences of hormone exposure depend on receptor distribution, dose, route, timing and duration. In menopause care, the most established role of systemic therapy is treatment of troublesome vasomotor symptoms, with local therapy particularly useful for genitourinary symptoms. In other endocrine disorders, replacement can be essential because severe hormone deficiency can impair multiple physiological systems. Accurate interpretation therefore requires identifying which hormone is being replaced, why it is being replaced, which preparation is used and what outcomes are intended.
